Neurogene Inc.
A biotechnology company that engineers gene therapies for rare, severe neurological diseases, mostly affecting children, such as Rett syndrome. Its EXACT technology acts like a built-in dial, fine-tuning how much of a therapeutic protein a cell makes to avoid the toxicity that often plagues conventional gene therapy. The company was founded in 2018 by Rachel McMinn, a biotech analyst whose older brother lives with an undiagnosed neurological condition—the personal spark behind the whole venture—and it went public in 2023 through a reverse merger.
Bought 6.67M
Granted 580.7K · Bought 569.0K
Bought 194.3K · Sold 19.7K
Bought 6.10M
Bought 48.8K
Sold 34.9K
Granted 49.8K · Bought 47.5K · Sold 3.4K
Bought 272.7K · Sold 50.0K
Bought 272.7K · Sold 259.9K
Sold 1.51M
Granted 74.2K · Bought 24.0K · Sold 25.5K
Granted 15.6K · Sold 15.6K
Granted 55.0K · Sold 23.7K
Granted 44.1K · Sold 13.6K
Granted 29.1K · Sold 29.1K
Granted 22.5K · Sold 6.3K
Granted 25.0K · Sold 6.5K
Granted 13.3K · Sold 828
Bought 5.2K
Granted 3.9K · Sold 3.9K
Bought 400
Granted 37.2K · Sold 37.2K
Granted 36.5K
Granted 36.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +3 co-filers10% owner · 81 transactions | — | 17.05Mas of Jan 2017 | — | 6.67M | — |
| Drachman Jonathan GPresident and CEO, Director · 17 transactions | — | 9.12Mas of Oct 2021 | 580.7K | 569.0K | — |
| Green Jeremy +1 co-filer10% owner · 13 transactions | — | 7.91Mas of Apr 2020 | — | 194.3K | 19.7K |
| Baker Bros. Advisors LP +5 co-filersDirector, 10% owner · 30 transactions | — | 6.24Mas of Dec 2023 | — | 6.10M | — |
| Akkaraju Srinivas +2 co-filers10% owner · 4 transactions | — | 1.67Mas of Nov 2024 | — | 48.8K | — |
| Walkey CarlSenior Vice President · 26 transactions | — | 1.35Mas of Jun 2021 | — | — | 34.9K |
| McMinn RachelChief Executive Officer, Director · 4 transactions | — | 1.34M | 49.8K | 47.5K | 3.4K |
| Johnson & Johnson +1 co-filer10% owner · 18 transactions | — | 1.34Mas of Dec 2014 | — | 272.7K | 50.0K |
| Pfizer Inc10% owner · 19 transactions | — | 1.24Mas of Aug 2015 | — | 272.7K | 259.9K |
| Johnson & Johnson +1 co-filer10% owner · 2 transactions | — | 100.0Kas of Aug 2015 | — | — | 1.51M |
| Cvijic Christine MikailPresident and CFO, Director · 12 transactions | — | 98.4K | 74.2K | 24.0K | 25.5K |
| Main DavidPresident and CEO, Director · 9 transactions | — | 71.5Kas of Jun 2017 | 15.6K | — | 15.6K |
| Patel PritiFormer Chief Medical Officer · 6 transactions | — | 37.3Kas of Apr 2023 | 55.0K | — | 23.7K |
| Cobb StuartChief Scientific Officer · 7 transactions | — | 30.5K | 44.1K | — | 13.6K |
| Alam KamranCFO, Vice President Finance · 3 transactions | — | 29.1Kas of Aug 2015 | 29.1K | — | 29.1K |
| Smith Sean MichaelInterim CFO, Prin Acct Off · 6 transactions | — | 21.6Kas of Aug 2023 | 22.5K | — | 6.3K |
| Ho RobertChief Financial Officer · 2 transactions | — | 21.5Kas of Mar 2021 | 25.0K | — | 6.5K |
| Jordan JulieChief Medical Officer · 3 transactions | — | 12.5K | 13.3K | — | 828 |
| Mitchell David ChiltonVP Global Regulatory & Quality · 2 transactions | — | 5.2Kas of Aug 2015 | — | 5.2K | — |
| Levitt Daniel JDirector · 2 transactions | — | 3.9Kas of May 2018 | 3.9K | — | 3.9K |
| Shrewsbury Stephen BCMO, Senior VP Clinical Dev. · 1 transaction | — | 400as of Sep 2014 | — | 400 | — |
| MacKenzie LloydChief Operating Officer · 5 transactions | — | 0as of Mar 2018 | 37.2K | — | 37.2K |
| Bridger GaryDirector · 9 transactions | — | 0as of Oct 2015 | 36.5K | — | — |
| Ventures West 8 Limited Partnership10% owner · 8 transactions | — | 0as of Mar 2014 | 36.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +12.16M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.